



(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/519 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2020/061548

(22) International Filing Date:

20 November 2020 (20.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/939,377 22 November 2019 (22.11.2019) US
63/050,416 10 July 2020 (10.07.2020) US
63/091,192 13 October 2020 (13.10.2020) US

(71) Applicant: SENDA BIOSCIENCES, INC. [US/US]; 20 Acorn Park Drive, Suite 300, Cambridge, Massachusetts 02140 (US).

(72) Inventors: BARTOLOZZI, Alessandra; 1011 North Lane, Gladwyne, Pennsylvania 19035 (US). PROUD-FOOT, John Robert; 40 Currituck Road, Newtown, Connecticut 06470 (US). BRIGGS, Timothy; 105 Vernon Street, Unit 2, Waltham, Massachusetts 02453 (US). MANCUSO, John; 35 34th Avenue, Sainte-Marthe-Sur-Le-Lac, Québec J0N 1P0 (CA). BONEPALLY, Karunakar Reddy; 7060 Rue Birnam, Apartment #4, Montreal, Québec H3N 2S7 (CA). BUREAU, Patrick; 93 Timberlea Trail, Kirkland, Québec H9J 2T3 (CA). GUO, Tianlin; 6060 Rue Emile-Nelligan, Apartment 308, Montreal, Québec H4J 1G5 (CA). BOS, Maxence; 6512 Avenue Henri Julien, Montreal, Québec H2S 2V2 (CA). BLOIS, Anna; 94 Louise Road, Chestnut Hill, Massachusetts 02467 (US). LANTER, Bernard; 260 Highland Avenue, Somerville, Massachusetts 02143 (US). TAYLOR, Steven John; 17 Hill Street, Winchester, Massachusetts 01890 (US). BUCK-BINDER, Leonard; 61 Spencer Avenue, East Greenwich, Rhode Island 02818 (US). BARONE, Francesca; 15 Greswolde Road, Solihull West Midlands B91 1DY (GB).

(74) Agent: MACALPINE, Jill K.; Finnegan, Henderson, Farabow, Garrett & Dummer, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS



(Ia)

(57) Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.

